Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 5/20 | 0.34 |
| ▸ | HTR2C | P28335 | 3/20 | 0.34 |
| ▸ | HTR2B | P41595 | 3/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.31 |
| ▸ | CDK9 | P50750 | 3/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24006341 | 0.88 | — | — | |
| SCHEMBL26330032 | 0.86 | IRAK4 (0.34) | ADRA1AADRA1DEHMT2SIGMAR1 | |
| SCHEMBL24006324 | 0.83 | SIGMAR1 (0.41) | ADRA1AHTR2CHTR2BEHMT2SIGMAR1 | |
| SCHEMBL25831641 | 0.81 | EHMT2 (0.38) | ADRA1AEHMT2 | |
| SCHEMBL25820202 | 0.79 | HTR2A (0.47) | HTR2CHTR2B | |
| SCHEMBL24003783 | 0.77 | EHMT2 (0.37) | EHMT2SIGMAR1 | |
| SCHEMBL25831479 | 0.76 | EHMT2 (0.37) | EHMT2SIGMAR1 | |
| SCHEMBL26311886 | 0.73 | ADRA1A (0.61) | ADRA1AADRA1DDRD2DRD3 | |
| SCHEMBL26330021 | 0.71 | ADRA1A (0.39) | ADRA1AADRA1DADRA2ADRD2DRD3 | |
| SCHEMBL24003942 | 0.70 | ADRA1A (0.36) | ADRA1AADRA1DADRA2ADRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | ADRA1A 3488/4885HTR2C 2539/4885HTR2B 3066/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | ADRA1A 2976/4885HTR2C 2111/4885HTR2B 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.